secwatch.observer — SEC 8-K summary
======================================

Issuer:     IDEXX LABORATORIES INC /DE (IDXX)
CIK:        0000874716
Form:       8-K
Filed at:   2026-02-02T23:59:59+00:00
Accession:  0001104659-26-008904
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IDEXX Q4 revenue $1.09B (+14% YoY), EPS $3.08 (+18%); guides FY26 rev $4.63B-$4.72B
--------------------------------------------------------------------------------

- Q4 revenue $1,091M (+14% as reported, +12% organic); EPS $3.08 (+18% as reported, +17% comparable).
- Full year 2025 revenue $4,304M (+10%); EPS $13.08 (+23% reported, +14% comparable).
- CAG Diagnostics recurring revenue grew 12% reported; record >1,900 IDEXX inVue Dx placements in Q4.
- FY26 guidance: rev $4,632M-$4,720M (7.6%-9.6% reported growth); EPS $14.29-$14.80 (9%-13% growth).
- Operating margin expanded 150 bps reported in Q4 to 28.9%; gross margin 60.3%, up 50 bps.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/874716/000110465926008904/0001104659-26-008904-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/874716/000110465926008904/tm264623d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-008904

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer